RxDoctor Payments Data

Whitney Wilson, APRN

Psychiatric/Mental Health · Tallahassee, FLNPI 1528602497

Payments from drug & device makers

$5,378in general payments, 2019–2025

Across 278 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$753
  • Alkermes, Inc.$703
  • Vanda Pharmaceuticals Inc.$685
  • Supernus Pharmaceuticals, Inc.$348
  • Zimmer Biomet$252
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$5,30499%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,378 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$11,616
Medicare patients
30
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon15$335,707
VraylarCariprazine Hcl84$120,747
RexultiBrexpiprazole38$66,221
LybalviOlanzapine/Samidorphan Malate14$24,057
CaplytaLumateperone Tosylate12$23,094
TrintellixVortioxetine Hydrobromide20$13,669
Aripiprazole78$11,710
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine60$2,319
Quetiapine Fumarate110$1,496
Oxcarbazepine18$1,313
Olanzapine69$1,228
Duloxetine Hcl57$1,204
Clonazepam176$1,160
Prazosin Hcl77$1,102
Divalproex Sodium ErDivalproex Sodium25$991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$685$335,70715 claims
AbbVieVraylar$1,085$120,74784 claims
Otsuka America Pharmaceutical, Inc.Rexulti$753$66,22138 claims
Alkermes, Inc.Lybalvi$703$24,05714 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$229$23,09412 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$54$13,66920 claims
Almatica Pharma LLCSertraline Hcl$60$477116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →